Seelos Therapeutics, Inc. (SEEL) stock declined over -9.97% intraday to trade at $0.9002 a share on NASDAQ. The stock opened with a loss of -4.23% at $0.97 and touched an intraday high of $1.04, falling -9.98% against the last close of $1. The stock went to a low of $0.9 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Seelos Therapeutics, Inc. (NASDAQ: SEEL) stock price is $0.9002 as of the last check on Monday, August 8. During the trading session, SEEL stock reached the peak price of $1.04 while $0.9 was the lowest point it dropped to.
The NASDAQ listed SEEL is part of Pharmaceuticals industry that operates in the broader Health Care sector. Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders.
Dr. Raj Mehra J.D., Ph.D.
Founder, Chairman, CEO & Pres
Mr. Michael J. Golembiewski
Chief Financial Officer
Ms. Kimberly Farrand
Sr. Director of Clinical Devel. & Operations
Mr. Anthony Marciano
Chief Communications Officer
SEEL stock traded closed the last session at $0.9, which is -$0.09970000000000001 or -9.970997099709972% lower than its previous close of $1. SEEL's current trading price is 87.42% lower than its 52-week high of $2.79 where as its distance from 52-week low of 0.48% is -67.73%.
Number of SEEL employees currently stands at -. SEEL operates from 300 Park Avenue, 2nd Floor, New York, NY 10022, United States.
Official Webiste of $SEEL is: https://seelostherapeutics.com
SEEL stock volume for the day was 1,218,314 shares while in the previous session number of SEEL shares traded was 1,184,558 . The average number of SEEL shares traded daily for last 3 months was 1.2 Million.
The percentage change in SEEL stock occurred in the recent session was -9.970997099709972% while the dollar amount for the price change in SEEL stock was -$0.09970000000000001.
In the recent session, the day high for SEEL stock was $1.04 while the low for SEEL stock touched on the day was $0.9.
The market value of SEEL currently stands at 92.9 Million with its latest stock price at $0.9002 and 105.53 Million of its shares outstanding.